Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EzAMI Trial
NCT04701242Recruiting
- Sponsor
- Cairo University
- Start
- Mar 2021
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, single-blind trial of ezetimibe in acute myocardial infarction (AMI) and dyslipidemia (2 arms), sponsored by Cairo University. Primary endpoints: Percentage of patients achieving target LDL-C levels (<70 mg/dl) at 6 weeks and Freedom from ALT elevation >3x URL or muscle pains with CK >4x URL at 6 weeks. Started Mar 2021; status: recruiting.
02
Drugs
ezetimibe
03
Conditions
acute myocardial infarction (AMI)dyslipidemia
Beyond the preview
Go deeper on NCT04701242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04701242.